Trial Profile

A Randomized, Placebo-controlled, Double-blind, Single-ascending-dose and Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of IV NTR-441 Solution in HV Adults and COVID-19 Patients

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NTR 441 (Primary)
Indications Autoimmune disorders; COVID 2019 infections; Systemic lupus erythematosus
Focus Adverse reactions; First in man
Sponsors Neutrolis Therapeutics

18 Jan 2024 Status changed from recruiting to discontinued because of insufficient enrollment due to emergence of omicron variant of COVID-19.
27 Sep 2022 Planned End Date changed from 1 Jun 2022 to 1 Nov 2022.
27 Sep 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Nov 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com